TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20479282

Group type: EXPERIMENTAL
Intervention: 11-gene model including 4 functional pathways (cell cycle, apoptosis, macrophage activation, and interferon regulatory factor 4)
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Final predictive model combining stage IV
Number of subjects: 282
Study: 19020155

Group type: COMPARATOR
Intervention: Fentanyl (three bolus of 1 microg x kg(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine (infusion of 15 microg x kg(‐1) x min(‐1))
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ketamine and fentanyl (infusion of 15 microg x kg(‐1) x min(‐1) ketamine plus three bolus of 1 microg x kg(‐1) fentanyl)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lornoxicam (one bolus of 8 mg)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Lornoxicam and fentanyl (one bolus of 8 mg lornoxicam plus three bolus of 1 microg x kg(‐1) fentanyl)
Number of subjects: 90
Study: 15750152

Group type: EXPERIMENTAL
Intervention: 18F‐FET PET
Number of subjects: 38

Group type: COMPARATOR
Intervention: 18F‐FDG PET
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Subgroup analysis of 18F‐FET PET in head-neck carcinomas
Number of subjects: 38
Study: 12036083

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1 g/day
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 5 g/day
Number of subjects: 620

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 10 g/day
Number of subjects: 620

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 620
Study: 10602891

Group type: EXPERIMENTAL
Intervention: 5FU/LMS therapy
Number of subjects: 38
Study: 7549345

Group type: EXPERIMENTAL
Intervention: 0.25% timolol in Gelrite administered once daily (TG)
Number of subjects: 156

Group type: COMPARATOR
Intervention: 0.25% timolol solution administered twice daily (TS)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: 0.25% timolol in Gelrite (TG)
Number of subjects: 156
Study: 2202283

Group type: EXPERIMENTAL
Intervention: Opsite alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Opsite after application of bupivacaine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scarlet ointment dressing alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Scarlet ointment after bupivacaine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Opsite
Number of subjects: 0

Group type: COMPARATOR
Intervention: Scarlet ointment
Number of subjects: 0
Study: 6972732

Group type: EXPERIMENTAL
Intervention: nalidixic acid (NA), 1 g every 6 h for 7 days
Number of subjects: 135

Group type: COMPARATOR
Intervention: trimethoprim/sulfamethoxazole (TMP/SMZ), 160/800 mg every 12 h for 10 days
Number of subjects: 135
Study: 31661738

Group type: EXPERIMENTAL
Intervention: Nutri-Score
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Multiple Traffic Lights (MTL)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Warning Symbol
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Health Star Rating system (HSR)
Number of subjects: 1001

Group type: EXPERIMENTAL
Intervention: Reference Intakes (RIs)
Number of subjects: 1001
Study: 27432173

Group type: EXPERIMENTAL
Intervention: Colonoscopic decompression
Number of subjects: 2

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 2
Study: 25922451

Group type: EXPERIMENTAL
Intervention: Short metaphyseal fixation (SMF) stem
Number of subjects: 43

Group type: COMPARATOR
Intervention: Standard-length tapered Synergy metaphyseal fixation stem
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 43
Study: 24103528

Group type: EXPERIMENTAL
Intervention: EGFR mutation detection by DHPLC
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: K-RAS mutation detection by direct sequencing
Number of subjects: 127
Study: 21438171

Group type: EXPERIMENTAL
Intervention: eFlow® nebulizer (100 mg/ml tobramycin solution, 1.5 ml)
Number of subjects: 16

Group type: COMPARATOR
Intervention: PARI LC PLUS® nebulizer (300 mg at 60 mg/ml tobramycin)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Comparison of delivery times
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Tolerability of treatment
Number of subjects: 16
Study: 19289727

Group type: EXPERIMENTAL
Intervention: Faculty calibration training (three two-hour training sessions)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 12
Study: 16167971

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg am and 20 mg pm for 7 days
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study: 12800605

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan (60 mg/m2 on days 1 and 8) plus carboplatin (AUC 4.0 on day 1, every 28 days)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Weekly irinotecan (90 mg/m2 on days 1 and 8) plus carboplatin (AUC 2.0 on days 1 and 8, every 21 days)
Number of subjects: 53
Study: 10233192

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg AM + Ranitidine 150 mg HS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Omeprazole 20 mg b.d. AC
Number of subjects: 20
Study: 8554479

Group type: EXPERIMENTAL
Intervention: Trunk flexor and extensor endurance tests
Number of subjects: 190

Group type: COMPARATOR
Intervention: New method for measuring lumbar lordosis
Number of subjects: 190
Study: 1762809

Group type: COMPARATOR
Intervention: Conventional continuous stimulation (70 Hz)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Burst stimulation (90 msec trains of pulses, 100 Hz internal frequency, 2 Hz repetition)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Frequency-modulated stimulation (90 Hz to 55 Hz over 90 msec)
Number of subjects: 27
Study: 6811217

Group type: EXPERIMENTAL
Intervention: Short-course chemotherapy (rifampicin, isoniazid, ethambutol until sensitivity tests completed, then isoniazid alone for four months)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Two-year chemotherapy scheme (rifampicin, isoniazid, ethambutol until culture conversion, then isoniazid alone for two years)
Number of subjects: 168
Study: 31106835

Group type: EXPERIMENTAL
Intervention: cetuximab
Number of subjects: 14

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 14
Study: 27964770

Group type: EXPERIMENTAL
Intervention: Coping and communication skills intervention (CCI)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Supportive counseling (SC)
Number of subjects: 201
Study: 25926350

Group type: EXPERIMENTAL
Intervention: 20 μg Novaferon injected 3 times per week
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 20 μg Novaferon injected twice per week
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: 40 μg Novaferon injected 3 times per week
Number of subjects: 108

Group type: COMPARATOR
Intervention: Saline injected 3 times per week (placebo)
Number of subjects: 108
Study: 23352226

Group type: EXPERIMENTAL
Intervention: FF/VI 100/25 μg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: FF/VI 50/25 μg
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: VI 25 μg
Number of subjects: 1030
Study: 21275961

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide + placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Magnesium + placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Hydroxycarbamide + Magnesium
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo + placebo
Number of subjects: 36
Study: 19864407

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 335
Study: 17712588

Group type: EXPERIMENTAL
Intervention: Pergolide (mean dose 2.93 ± 0.75 mg per day, range 0.75 to 5 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (36 subjects, mean age 55.0 ± 12.8 years)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Pergolide (mean dose 2.93 ± 0.75 mg per day)
Number of subjects: 90
Study: 15856361

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg daily (n=12)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Anastrozole 1 mg twice weekly (n=11)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo (n=14)
Number of subjects: 37
Study: 12424712

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (3 million units subcutaneously three times weekly) plus ribavirin (800 to 1,000 mg/d) for 12 months
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b plus ribavirin
Number of subjects: 54
Study: 10482176

Group type: EXPERIMENTAL
Intervention: Cariporide (HOE 642) 40 mg intravenous bolus prior to reperfusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7661176

Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 8

Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Isotonic saline (Control)
Number of subjects: 8
Study: 1755159

Group type: EXPERIMENTAL
Intervention: Lipoic acid administered in complex with tyrosine catabolism cofactors (pyridoxal phosphate, ascorbic acid, iron ions)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoic acid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipoic acid in complex with vitamins B1, B2, B5 (PP), B6 (pyridoxal phosphate), C
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study: 7048246

Group type: EXPERIMENTAL
Intervention: Isaxonine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31502886

Group type: EXPERIMENTAL
Intervention: VATS + LMWH
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: VATS no LMWH
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Thoracotomy + LMWH
Number of subjects: 93

Group type: COMPARATOR
Intervention: VATS patients
Number of subjects: 93

Group type: COMPARATOR
Intervention: Thoracotomy patients
Number of subjects: 93
Study: 28926857

Group type: EXPERIMENTAL
Intervention: High-salt diet with potassium supplementation (4.5 g/day, KCl)
Number of subjects: 45

Group type: COMPARATOR
Intervention: High-salt diet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Low-salt diet to high-salt diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: High-salt diet to potassium supplementation
Number of subjects: 45
Study: 27160842

Group type: EXPERIMENTAL
Intervention: TARGIT
Number of subjects: 485

Group type: COMPARATOR
Intervention: EBRT
Number of subjects: 485
Study: 25122430

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/d
Number of subjects: 1060
Study: 22225997

Group type: EXPERIMENTAL
Intervention: Tailored training of household heads about the proper use of LLITN and community network system
Number of subjects: 2612
Study: 19281935

Group type: EXPERIMENTAL
Intervention: IV hydromorphone (0.0075 mg/kg)
Number of subjects: 194

Group type: COMPARATOR
Intervention: IV morphine (0.05 mg/kg)
Number of subjects: 194
Study: 17635381

Group type: EXPERIMENTAL
Intervention: Multispecies probiotic supplementation
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 55
Study: 15140452

Group type: EXPERIMENTAL
Intervention: Integral checklist intervention
Number of subjects: 229

Group type: COMPARATOR
Intervention: Control group (no checklist)
Number of subjects: 229
Study: 12216046

Group type: EXPERIMENTAL
Intervention: Tap water irrigation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal saline irrigation
Number of subjects: 46
Study: 9666826

Group type: EXPERIMENTAL
Intervention: Cetirizine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Bradykinin
Number of subjects: 10
Study: 8590551

Group type: EXPERIMENTAL
Intervention: Mental distraction (SB + word puzzle)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mental stress (SB + computer quiz)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Conscious control of breathing (paced at SB rate)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (spontaneous breathing)
Number of subjects: 30
Study: 2667638

Group type: COMPARATOR
Intervention: minus lenses with full correction for continuous use (the reference group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: minus lenses with full correction to be used for distant vision only
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: bifocal lenses with +1.75 D addition
Number of subjects: 240
Study: 821802

Group type: EXPERIMENTAL
Intervention: Killed oral typhoid vaccine from the German Democratic Republic (GDR)
Number of subjects: 75083

Group type: EXPERIMENTAL
Intervention: Killed oral typhoid vaccine from the German Federal Republic (GFR)
Number of subjects: 75083

Group type: COMPARATOR
Intervention: Placebo (control group for GDR vaccine)
Number of subjects: 75083

Group type: COMPARATOR
Intervention: Placebo (control group for GFR vaccine)
Number of subjects: 75083
Study: 29509918

Group type: EXPERIMENTAL
Intervention: Unchanged L‐T4 dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Higher L‐T4 dose
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Lower L‐T4 dose
Number of subjects: 138

Group type: COMPARATOR
Intervention: All groups (Unchanged, Higher, Lower)
Number of subjects: 138
Study: 26437957

Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg/daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Citalopram 20 mg/daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25459793

Group type: EXPERIMENTAL
Intervention: Happy affective expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral affective expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angry affective expression
Number of subjects: 0
Study: 22741474

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine decoction (supplementing qi and nourishing yin recipe)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Medroxyprogesterone acetate (depogeston)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine decoction
Number of subjects: 106

Group type: COMPARATOR
Intervention: Traditional Chinese medicine decoction and Medroxyprogesterone acetate
Number of subjects: 106
Study: 20368909

Group type: EXPERIMENTAL
Intervention: Essential amino acid supplementation (EAAs) embedded in a 12-week rehabilitation program
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (C) receiving the same program without supplementation
Number of subjects: 28
Study: 18381508

Group type: EXPERIMENTAL
Intervention: School Nutrition Policy Initiative
Number of subjects: 1349

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1349
Study: 16044002

Group type: EXPERIMENTAL
Intervention: Continuous HAART
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: CD4-guided treatment
Number of subjects: 74

Group type: COMPARATOR
Intervention: Week-on-week-off treatment
Number of subjects: 74
Study: 12633122

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 94

Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 94
Study: 10622646

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 16

Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 16
Study: 8620717

Group type: EXPERIMENTAL
Intervention: Lisinopril (four daily doses)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (matched placebo)
Number of subjects: 10
Study: 1954354

Group type: EXPERIMENTAL
Intervention: High-dose Ara‐C (3 g/m2 IV over 1 h every 12 h eight times followed by 25 mg/m2 per day daunorubicin IV bolus for 2 days)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional consolidation therapy (200 mg/m2 of behenoyl‐arabino‐furanosylcytosine for 7 days and 25 mg/m2 of daunorubicin for 2 to 3 days)
Number of subjects: 27
Study: 6257941

Group type: EXPERIMENTAL
Intervention: Warfarin sodium
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (no warfarin)
Number of subjects: 50
Study: 29905630

Group type: EXPERIMENTAL
Intervention: Stimulation (n = 4) for 5 minutes followed by continuous stimulation until lead removal on postoperative days 14 to 28.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Stimulation (n = 7) for 30 minutes after initial treatment.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Continuous stimulation with active stimulation (n = 7).
Number of subjects: 7

Group type: COMPARATOR
Intervention: Sham (n = 3) for 5 minutes followed by crossover to stimulation.
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Rescue analgesia with continuous popliteal nerve block (n = 7).
Number of subjects: 7
Study: 27737774

Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (33°C)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Therapeutic normothermia (36.8°C)
Number of subjects: 54
Study: 24670156

Group type: EXPERIMENTAL
Intervention: Cosmetics use by women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-applied cosmetics by models
Number of subjects: 0
Study: 22520518

Group type: EXPERIMENTAL
Intervention: Target temperature management of 33°C
Number of subjects: 850

Group type: COMPARATOR
Intervention: Target temperature management of 36°C
Number of subjects: 850
Study: 20171597

Group type: EXPERIMENTAL
Intervention: Tetrathiomolybdate therapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 18572080

Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg twice daily (n=1637)
Number of subjects: 3172

Group type: COMPARATOR
Intervention: Placebo (n=1640)
Number of subjects: 3172

Group type: EXPERIMENTAL
Intervention: Aciclovir 400 mg twice daily
Number of subjects: 3172
Study: 16094268

Group type: EXPERIMENTAL
Intervention: rhBMP-2/CRM
Number of subjects: 74

Group type: COMPARATOR
Intervention: ICBG
Number of subjects: 74
Study: 12452026

Group type: EXPERIMENTAL
Intervention: Intraperitoneal infusion of warm (43 degrees C‐45 degrees C) distilled water (1,250 ml/m2) plus 5‐fluorouracil (500 mg/L) after radical gastrectomy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraperitoneal infusion of warm (43 degrees C‐45 degrees C) distilled water (1,250 ml/m2) plus 5‐fluorouracil (500 mg/L) before operation
Number of subjects: 50
Study: 11116771

Group type: EXPERIMENTAL
Intervention: Counselling
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 323

Group type: COMPARATOR
Intervention: Patient preference for treatment
Number of subjects: 323
Study: 9105813

Group type: EXPERIMENTAL
Intervention: St. Jude (SJ) valve
Number of subjects: 80

Group type: COMPARATOR
Intervention: Medtronic Hall (MH) valve
Number of subjects: 80
Study: 1486900

Group type: EXPERIMENTAL
Intervention: Loop diuretics (e.g. furosemide 40 mg, torasemide 5 and 10 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loop diuretics (muzolimine 20 mg, torasemide 2.5 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Thiazide-type diuretics (e.g. hydrochlorothiazide 25 and 50 mg, xipamide 10, 20 and 40 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Loop diuretics
Number of subjects: 30
Study: 2428187

Group type: EXPERIMENTAL
Intervention: Aggregation inhibitors, low heparin dosage, and preoperative normovolaemic haemodilution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30928824

Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 or 150 mg bid, plus clopidogrel or ticagrelor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin triple therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dabigatran dual therapy (110 or 150 mg)
Number of subjects: 0
Study: 29779020

Group type: EXPERIMENTAL
Intervention: Intravenous acetaminophen (4 g/day for 72 postoperative hours)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 140
Study: 26915299

Group type: EXPERIMENTAL
Intervention: Intrapulmonary percussive ventilation in upright position (IPVR) for 20 minutes, 2 hours after feeding
Number of subjects: 50
Study: 25686117

Group type: EXPERIMENTAL
Intervention: Pre‐emptive treatment
Number of subjects: 95

Group type: COMPARATOR
Intervention: Reactive treatment
Number of subjects: 95
Study: 23921857

Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen (800 mg starting 1 hour before misoprostol, then every 4-6 hours for 48 hours regardless of pain)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Therapeutic ibuprofen (800 mg every 4-6 hours as needed for pain)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Prophylactic ibuprofen
Number of subjects: 250

Group type: COMPARATOR
Intervention: Therapeutic ibuprofen
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250
Study: 19879035

Group type: EXPERIMENTAL
Intervention: Prednisone plus oral azathioprine for 24 months (AZA group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Prednisone plus intravenous cyclophosphamide pulses (CIC group)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 46
Study: 18379360

Group type: EXPERIMENTAL
Intervention: I 160 mg/m(2) plus D 60 mg/m(2) on day 1 every 21 days (arm A)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: I 80 mg/m(2) on days 1,8 plus D 60 mg/m(2) on day 1 every 21 days (arm B)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: I 60 mg/m(2) plus D 30 mg/m(2) on days 1, 8, 15, and 22 every 42 days (arm C)
Number of subjects: 65
Study: 16601869

Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) administration (25 mg/kg per day, divided into three daily doses)
Number of subjects: 4
Study: 14617464

Group type: EXPERIMENTAL
Intervention: Intramuscular iron dextran
Number of subjects: 60

Group type: COMPARATOR
Intervention: Oral ferrous sulphate
Number of subjects: 60
Study: 10887918

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 829

Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 829
Study: 8814046

Group type: EXPERIMENTAL
Intervention: Patients' perceptions of asthma severity
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Medication severity rating
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Diurnal variation rating
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Evening peak expiratory flow rate percentage
Number of subjects: 323
Study: 1403033

Group type: EXPERIMENTAL
Intervention: Escalating doses of doxorubicin and cyclophosphamide with vincristine and prednisone followed by 1 year of leukocyte alpha-interferon
Number of subjects: 319

Group type: COMPARATOR
Intervention: Escalating doses of doxorubicin and cyclophosphamide with vincristine and prednisone
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Doxorubicin administered by continuous infusion
Number of subjects: 319